FerroKin rounds up $12M for iron overload treatment

With the help of investors Burrill & Company, Celgene, Clarus Ventures, MP Healthcare Venture Management and Healthcap Ventures, San Francisco-based FerroKin Biosciences has raised a $12 million round of financing. The company is developing FBS0701, a treatment for iron overload disease. The oral drug, an iron chelator indicated for transfusional iron overload, has been granted orphan drug designation by both the FDA and EMA. The developer has already completed three...